Aurobindo Pharma plunges 8% on USFDA warning
Synopsis
This action follows the earlier inspection of the site by the USFDA in February 2019.
This action follows the earlier inspection of the site by the USFDA in February 2019.
The company said that its existing business from this facility will not be impacted and it will be engaging with the regulator and are fully committed to resolving this issue at the earliest.
"We are also committed to maintaining the highest quality manufacturing standards at all of its facilities across the globe," it added.
Shares of Aurobindo Pharma closed 3.92 per cent down at Rs 602.35 on BSE.